Bio Atla, Inc. BCAB
We take great care to ensure that the data presented and summarized in this overview for BioAtla, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding BCAB
View all-
Acorn Capital Advisors, LLC New York, NY4.84MShares$1.79 Million1.25% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.78MShares$659,7640.0% of portfolio
-
Acadian Asset Management LLC Boston, MA1.49MShares$552,2440.0% of portfolio
-
Tang Capital Management LLC San Diego, CA1.37MShares$508,4080.03% of portfolio
-
Black Rock Inc. New York, NY792KShares$292,8770.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny754KShares$279,0690.0% of portfolio
-
Deutsche Bank Ag\ Frankfurt Am Main, 2M525KShares$194,3800.0% of portfolio
-
Geode Capital Management, LLC Boston, MA492KShares$182,1350.0% of portfolio
-
Morgan Stanley New York, NY316KShares$116,7610.0% of portfolio
-
Adar1 Capital Management, LLC Austin, TX171KShares$63,0870.01% of portfolio
Latest Institutional Activity in BCAB
Top Purchases
Top Sells
About BCAB
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.
Insider Transactions at BCAB
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 18
2025
|
Susan Moran |
BUY
Grant, award, or other acquisition
|
Direct |
23,500
+31.0%
|
-
|
|
Jun 18
2025
|
Scott Andrew Smith |
BUY
Grant, award, or other acquisition
|
Direct |
23,500
+6.81%
|
-
|
|
Jun 18
2025
|
Sylvia Mcbrinn |
BUY
Grant, award, or other acquisition
|
Direct |
23,500
+28.44%
|
-
|
|
Jun 18
2025
|
Mary Ann Gray |
BUY
Grant, award, or other acquisition
|
Direct |
23,500
+23.29%
|
-
|
|
Jun 18
2025
|
Lawrence Steinman |
BUY
Grant, award, or other acquisition
|
Direct |
23,500
+23.05%
|
-
|
|
Jun 18
2025
|
Eddie Williams |
BUY
Grant, award, or other acquisition
|
Direct |
23,500
+28.08%
|
-
|
|
May 31
2025
|
Christian Vasquez |
SELL
Payment of exercise price or tax liability
|
Direct |
1,566
-0.55%
|
$0
$0.41 P/Share
|
|
May 31
2025
|
Richard A Waldron Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,371
-0.69%
|
$0
$0.41 P/Share
|
|
May 31
2025
|
Eric Sievers Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,729
-0.74%
|
$0
$0.41 P/Share
|
|
May 31
2025
|
Jay M Phd Short Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,347
-0.28%
|
$0
$0.41 P/Share
|
|
Mar 12
2025
|
Jay M Phd Short Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
431,000
+16.04%
|
-
|
|
Mar 11
2025
|
Eric Sievers Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
175,000
+32.11%
|
-
|
|
Mar 11
2025
|
Richard A Waldron Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+23.08%
|
-
|
|
Mar 11
2025
|
Christian Vasquez |
BUY
Grant, award, or other acquisition
|
Direct |
85,000
+23.5%
|
-
|
|
Feb 16
2025
|
Jay M Phd Short Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
30,911
-1.67%
|
$0
$0.46 P/Share
|
|
Feb 15
2025
|
Christian Vasquez |
SELL
Payment of exercise price or tax liability
|
Direct |
7,189
-3.61%
|
$0
$0.46 P/Share
|
|
Feb 15
2025
|
Richard A Waldron Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
10,887
-4.46%
|
$0
$0.46 P/Share
|
|
Feb 15
2025
|
Eric Sievers Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
12,530
-6.04%
|
$0
$0.46 P/Share
|
|
Aug 31
2024
|
Eric Sievers Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
572
-0.27%
|
$572
$1.77 P/Share
|
|
Aug 31
2024
|
Scott Andrew Smith |
SELL
Payment of exercise price or tax liability
|
Direct |
2,181
-0.73%
|
$2,181
$1.77 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 932K shares |
|---|
| Payment of exercise price or tax liability | 77.3K shares |
|---|